A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Completed · Phase 1
Conditions studied: Multiple Myeloma
In brief
Study PT-112-102, a multicenter, open-label dose-finding and pharmacokinetic study of PT-112 in patients with relapsed or refractory multiple myeloma. This is designed as a two-part study. In the first part of the study, cohorts of three patients (expanded to six patients in the event of a dose-limiting toxicity) will receive escalating doses of PT-112 until the MTD is reached, based on tolerability observed during the first 28 days of treatment. In the second part of the study, an expansion cohort of 14 patients will be treated at the recommended dose to confirm the tolerability of treatment and evaluate evidence of treatment efficacy.
Key facts
- Study ID
- NCT03288480
- Run by
- Promontory Therapeutics Inc.
- People needed
- 24
- Starts
- 2017-12-15
- Expected to finish
- 2021-03-01
- Last updated by the study team
- 2022-04-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Cancer Center — Phoenix, Arizona, United States
- Rocky Mountain Cancer Centers — Denver, Colorado, United States
- Mayo Clinic Cancer Center — Jacksonville, Florida, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Texas Oncology San Antonio Medical Center — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.